BIOMAT Database Logo BIOMAT Database Logo

Indinavir pharmacokinetics in haemodialysis-dependent end-stage renal failure. 1998

J M Guardiola, and M A Mangues, and P Domingo, and E Martínez, and J L Barrio

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D017320 HIV Protease Inhibitors Inhibitors of HIV PROTEASE, an enzyme required for production of proteins needed for viral assembly. HIV Protease Inhibitor,Inhibitor, HIV Protease,Inhibitors, HIV Protease,Protease Inhibitor, HIV,Protease Inhibitors, HIV
D019380 Anti-HIV Agents Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. AIDS Drug,AIDS Drugs,Anti-AIDS Agents,Anti-AIDS Drug,Anti-HIV Agent,Anti-HIV Drug,Anti-AIDS Drugs,Anti-HIV Drugs,Agent, Anti-HIV,Agents, Anti-AIDS,Agents, Anti-HIV,Anti AIDS Agents,Anti AIDS Drug,Anti AIDS Drugs,Anti HIV Agent,Anti HIV Agents,Anti HIV Drug,Anti HIV Drugs,Drug, AIDS,Drug, Anti-AIDS,Drug, Anti-HIV,Drugs, AIDS,Drugs, Anti-AIDS,Drugs, Anti-HIV
D019469 Indinavir A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. Crixivan,Indinavir Sulfate,Indinavir, Sulfate (1:1),L-735 524,L-735,524,MK-639,L 735 524,L 735,524,L735 524,L735,524,MK 639,MK639,Sulfate, Indinavir

Related Publications

J M Guardiola, and M A Mangues, and P Domingo, and E Martínez, and J L Barrio
Indinavir pharmacokinetics in haemodialysis.
July 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
J M Guardiola, and M A Mangues, and P Domingo, and E Martínez, and J L Barrio
Regular short haemodialysis in end-stage renal failure.
September 1975, British medical journal,
J M Guardiola, and M A Mangues, and P Domingo, and E Martínez, and J L Barrio
Pharmacokinetics of zidovudine in end-stage renal disease: influence of haemodialysis.
August 1992, AIDS (London, England),
J M Guardiola, and M A Mangues, and P Domingo, and E Martínez, and J L Barrio
Venetoclax pharmacokinetics in participants with end-stage renal disease undergoing haemodialysis.
March 2024, British journal of clinical pharmacology,
J M Guardiola, and M A Mangues, and P Domingo, and E Martínez, and J L Barrio
Pharmacokinetics of aliskiren in patients with end-stage renal disease undergoing haemodialysis.
October 2012, Clinical pharmacokinetics,
J M Guardiola, and M A Mangues, and P Domingo, and E Martínez, and J L Barrio
Pharmacokinetics of meloxicam in patients with end-stage renal failure on haemodialysis: a comparison with healthy volunteers.
January 1996, European journal of clinical pharmacology,
J M Guardiola, and M A Mangues, and P Domingo, and E Martínez, and J L Barrio
The pharmacokinetics of ofloxacin, desmethyl ofloxacin and ofloxacin N-oxide in haemodialysis patients with end-stage renal failure.
September 1988, The Journal of antimicrobial chemotherapy,
J M Guardiola, and M A Mangues, and P Domingo, and E Martínez, and J L Barrio
The pharmacokinetics of etanercept in patients with end-stage renal disease on haemodialysis.
November 2005, The Journal of pharmacy and pharmacology,
J M Guardiola, and M A Mangues, and P Domingo, and E Martínez, and J L Barrio
Pharmacokinetics of pantoprazole in patients with end-stage renal failure.
May 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
J M Guardiola, and M A Mangues, and P Domingo, and E Martínez, and J L Barrio
Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis.
April 2015, Thrombosis and haemostasis,
Copied contents to your clipboard!